The lncRNA ALPHA specifically targets chikungunya virus to control infection

Mol Cell. 2022 Oct 6;82(19):3729-3744.e10. doi: 10.1016/j.molcel.2022.08.030. Epub 2022 Sep 26.

Abstract

Arthropod-borne viruses, including the alphavirus chikungunya virus (CHIKV), cause acute disease in millions of people and utilize potent mechanisms to antagonize and circumvent innate immune pathways including the type I interferon (IFN) pathway. In response, hosts have evolved antiviral counterdefense strategies that remain incompletely understood. Recent studies have found that long noncoding RNAs (lncRNAs) regulate classical innate immune pathways; how lncRNAs contribute to additional antiviral counterdefenses remains unclear. Using high-throughput genetic screening, we identified a cytoplasmic antiviral lncRNA that we named antiviral lncRNA prohibiting human alphaviruses (ALPHA), which is transcriptionally induced by alphaviruses and functions independently of IFN to inhibit the replication of CHIKV and its closest relative, O'nyong'nyong virus (ONNV), but not other viruses. Furthermore, we showed that ALPHA interacts with CHIKV genomic RNA and restrains viral RNA replication. Together, our findings reveal that ALPHA and potentially other lncRNAs can mediate non-canonical antiviral immune responses against specific viruses.

Keywords: RNA-RNA interactions; alphavirus; innate antiviral immunity; long noncoding RNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiviral Agents / pharmacology
  • Chikungunya virus* / genetics
  • Humans
  • Immunity, Innate / genetics
  • Interferon Type I* / genetics
  • RNA, Long Noncoding* / genetics
  • RNA, Viral / genetics
  • Virus Replication / genetics

Substances

  • Antiviral Agents
  • Interferon Type I
  • RNA, Long Noncoding
  • RNA, Viral